Exciting Advances in Spinal Cord Injury Treatment
NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) is making significant progress in treating spinal cord injuries with its innovative therapy, ExoPTEN. A recent preclinical study has revealed compelling evidence that ExoPTEN can effectively target and localize at injury sites, even when administered up to seven days after the injury occurs. This extended timeframe provides a crucial opportunity for therapeutic intervention, potentially maximizing recovery for many patients.
Insights from the Preclinical Study
The study, which utilized a spinal cord compression model, demonstrated that ExoPTEN has a strong affinity for the injury site once introduced into the body. This was assessed through a series of timed administrations—on the day of injury (day zero), and then on days three, five, and seven. The results showed that ExoPTEN maintained a remarkable cumulative presence at the injury site, with particularly noteworthy outcomes when treatment was delayed by up to a week.
Impact on Patient Treatment Options
Dr. Lior Shaltiel, the CEO of the company, noted that these findings could significantly broaden the range of patients eligible for treatment. The ability to administer ExoPTEN within a week after injury brings hope to individuals who might have previously missed the chance for timely care. This is especially important given that the global incidence of spinal cord injuries is estimated to be between 250,000 and 500,000 each year.
Study Methodology
The research employed an advanced In Vivo Imaging System (IVIS) to track the behavior of ExoPTEN as it was administered to rats with spinal cord injuries. The results indicated a consistent accumulation of the therapy at the injury site, along with evidence of dose-dependent relationships, highlighting the precision and targeted nature of ExoPTEN as a therapeutic agent.
Potential for Enhanced Recovery and Clinical Use
These findings not only strengthen confidence in ExoPTEN's therapeutic potential but also pave the way for improved designs in clinical trials. The flexibility in treatment regimens will allow healthcare providers to better cater to patients suffering from central nervous system injuries, positioning NurExone as a leader in innovative treatment solutions.
About NurExone Biologic Inc.
As a pioneer in developing exosome-based therapies, NurExone Biologic Inc. is transforming how serious health issues related to central nervous system injuries are treated. Their flagship product, ExoPTEN, has demonstrated remarkable effectiveness in restoring motor functions in preclinical models and has received Orphan Drug Designation from the FDA, underscoring its importance in both clinical applications and market potential.
Contact Information for Further Inquiries
If you would like more information or are interested in discussing potential collaborations, you can reach out to NurExone's dedicated investor relations team:
Dr. Lior Shaltiel
Chief Executive Officer and Director
Phone: +972-52-4803034
Email: info@nurexone.com
Thesis Capital Inc.
Investor Relations - Canada
Phone: +1 905-347-5569
Email: IR@nurexone.com
Dr. Eva Reuter
Investor Relations - Germany
Phone: +49-69-1532-5857
Email: e.reuter@dr-reuter.eu
Allele Capital Partners
Investor Relations - US
Phone: +1 978-857-5075
Email: aeriksen@allelecapital.com
Frequently Asked Questions
What is ExoPTEN and how does it work?
ExoPTEN is an exosome-based therapy developed by NurExone aimed at promoting recovery in patients with spinal cord injuries. It effectively targets injury sites to enhance healing.
How long after a spinal cord injury can ExoPTEN be administered?
The study shows that ExoPTEN can be effectively administered up to seven days after the injury, significantly widening the treatment window.
What are the primary benefits of using ExoPTEN?
ExoPTEN improves targeting at injury sites, enhances recovery potential, and allows for more adaptable treatment regimens.
What does the FDA designation mean for ExoPTEN?
Receiving Orphan Drug Designation from the FDA facilitates the development process and may lead to quicker approval of ExoPTEN as a treatment for spinal cord injuries.
Who can I contact for more information about NurExone?
For inquiries, you can directly contact Dr. Lior Shaltiel or the investor relations teams in Canada, Germany, or the US using their provided contact details.
